To better understand the stage(s) of differentiation reached by B-type chronic lymphocytic leukemia (B-CLL) cells and to gain insight into the potential role of antigenic stimulation in the development and diversification of these cells, we analyzed the rearranged VH genes expressed by 83 B-CLL cells (64 IgM+ and 19 non-IgM+). Our results confirm and extend the observations of a bias in the use of certain VH, D, and JH genes among B-CLL cells. In addition, they indicate that the VH genes of approximately 50% of the IgM+ B-CLL cells and approximately 75% of the non-IgM+ B-CLL cells can exhibit somatic mutations. The presence of mutation varies according to the VH family expressed by the B-CLL cell (VH3 expressers displaying more mutation than VH1 and VH4 expressers). In addition, the extent of mutation can be sizeable with approximately 32% of the IgM+ cases and approximately 68% of the non-IgM+ cases differing by > 5% from the most similar germline gene. Approximately 20% of the mutated VH genes display replacement mutations in a pattern consistent with antigen selection. However, CDR3 characteristics (D and JH gene use and association and HCDR3 length, composition, and charge) suggest that selection for distinct B cell receptors (BCR) occurs in many more B-CLL cells. Based on these data, we suggest three prototypic BCR, representing the VH genes most frequently encountered in our study. These data suggest that many B-CLL cells have been previously stimulated, placing them in the "experienced" or "memory" CD5(+) B cell subset.
F Fais, F Ghiotto, S Hashimoto, B Sellars, A Valetto, S L Allen, P Schulman, V P Vinciguerra, K Rai, L Z Rassenti, T J Kipps, G Dighiero, H W Schroeder Jr, M Ferrarini, N Chiorazzi
Title and authors | Publication | Year |
---|---|---|
Combined Influence of B-Cell Receptor Rearrangement and Somatic Hypermutation on B-Cell Class-Switch Fate in Health and in Chronic Lymphocytic Leukemia
VN Petrova, L Muir, PF McKay, GS Vassiliou, KG Smith, PA Lyons, CA Russell, CA Anderson, P Kellam, RJ Bashford-Rogers |
Frontiers in immunology | 2018 |
Evolution of CLL treatment — from chemoimmunotherapy to targeted and individualized therapy
JA Burger, S OBrien |
Nature Reviews Clinical Oncology | 2018 |
Chronic Lymphocytic Leukemia–Derived IL-10 Suppresses Antitumor Immunity
SS Alhakeem, MK McKenna, KZ Oben, SK Noothi, JR Rivas, GC Hildebrandt, RA Fleischman, VM Rangnekar, N Muthusamy, S Bondada |
Journal of immunology (Baltimore, Md. : 1950) | 2018 |
Restricted T cell receptor repertoire in CLL-like monoclonal B cell lymphocytosis and early stage CLL
G Blanco, A Vardi, A Puiggros, A Gómez-Llonín, M Muro, M Rodríguez-Rivera, E Stalika, E Abella, E Gimeno, M López-Sánchez, A Senín, X Calvo, P Abrisqueta, F Bosch, A Ferrer, K Stamatopoulos, B Espinet |
OncoImmunology | 2018 |
Assessing human B cell repertoire diversity and convergence
K Imkeller, H Wardemann |
Immunological Reviews | 2018 |
The importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemia
E ten Hacken, M Gounari, P Ghia, JA Burger |
Leukemia | 2018 |
Double sword role of EZH2 in leukemia
S Safaei, B Baradaran, MF Hagh, MR Alivand, M Talebi, T Gharibi, S Solali |
Biomedicine & Pharmacotherapy | 2018 |
Preferential use of unmutated immunoglobulin heavy variable region genes in Boxer dogs with chronic lymphocytic leukemia
ED Rout, RC Burnett, JD Labadie, JA Yoshimoto, AC Avery, S Bondada |
PloS one | 2018 |
Strategies to overcome resistance mutations of Bruton's tyrosine kinase inhibitor ibrutinib
L Liu, B Shi, X Wang, H Xiang |
Future Medicinal Chemistry | 2018 |
Lymphoma-like monoclonal B cell lymphocytosis in a patient population: biology, natural evolution, and differences from CLL-like clones
SV Meeren, B Heyrman, W Renmans, M Bakkus, B Maes, HD Raeve, R Schots, K Jochmans |
Annals of Hematology | 2018 |
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
M Hallek, BD Cheson, D Catovsky, F Caligaris-Cappio, G Dighiero, H Döhner, P Hillmen, M Keating, E Montserrat, N Chiorazzi, S Stilgenbauer, KR Rai, JC Byrd, B Eichhorst, S OBrien, T Robak, JF Seymour, TJ Kipps |
Blood | 2018 |
Efficient lysis of B-chronic lymphocytic leukemia cells by the plant-derived sesquiterpene alcohol α-bisabolol, a dual proapoptotic and antiautophagic agent
A Rigo, I Ferrarini, A Bonalumi, C Tecchio, A Montresor, C Laudanna, F Vinante |
Oncotarget | 2018 |
A phase 2 study of ofatumumab (Arzerra ® ) in combination with a pan-AKT inhibitor (afuresertib) in previously treated patients with chronic lymphocytic leukemia (CLL)*
CI Chen, H Paul, LW Le, EN Wei, S Snitzler, T Wang, O Levina, S Kakar, A Lau, M Queau, JB Johnston, DA Smith, S Trudel |
Leukemia & Lymphoma | 2018 |
Immunoglobulin heavy chain variable region gene and prediction of time to first treatment in patients with chronic lymphocytic leukemia: Mutational load or mutational status? Analysis of 1003 cases
F Morabito, TD Shanafelt, M Gentile, G Reda, FR Mauro, D Rossi, ND Renzo, S Molica, F Angrilli, A Chiarenza, G Cutrona, KG Chaffee, SA Parikh, G Tripepi, G D'Arrigo, E Vigna, AG Recchia, A Cortelezzi, G Gaidano, FD Raimondo, F Fais, R Foà, A Neri, M Ferrarini |
American Journal of Hematology | 2018 |
Trisomy 12 chronic lymphocytic leukemia expresses a unique set of activated and targetable pathways
LV Abruzzo, CD Herling, GA Calin, C Oakes, LL Barron, HE Banks, V Katju, MJ Keating, KR Coombes |
Haematologica | 2018 |
A phase 2 study of lenalidomide and dexamethasone in previously untreated patients with chronic lymphocytic leukemia (CLL)
CI Chen, H Paul, S Snitzler, S Kakar, LW Le, EN Wei, A Lau, JB Johnston, SB Gibson, M Queau, D Spaner, D Croucher, B Sherry, S Trudel |
Leukemia & Lymphoma | 2018 |
Pathologie: Knochenmark, Lymphatisches System, Milz, Thymus
HK Müller-Hermelink, HH Kreipe |
2018 |